Market Analysis of Cephalosporins and Penicillins
Ceftiofur sodium, ceftiofur hydrochloride, cephalosporins fell as a whole, the average market transaction price, ceftiofur sodium 1860, down 18.1% year-on-year; ceftiofur hydrochloride 1380, down 20.0% year-on-year
The market price of cefquinoxime sulfate was 6420, a year-on-year decrease of 11.3%. Throughout the first half of the year, cephalosporin products fluctuated and declined, and the supply of various brands in the market was sufficient
Amoxicillin, high and volatile, the market price is 240-252, the transaction volume is flat, the transaction price is negotiable
Amoxicillin sodium, market price 535
Amoxicillin-clavulanate potassium, running smoothly, the average market transaction price is 835-865
Ampicillin, ampicillin sodium, the market price is stable, ampicillin 256, ampicillin sodium 303-365
Penicillin sodium (potassium), penicillin sodium market price 180-196/billion, penicillin potassium industrial salt price 123-133
Tetracycline and Chloramphenicol
Doxycycline hydrochloride, stable and improving, prices rose, entered July, rebounded slightly, and the trading market was stable
Oxytetracycline and oxytetracycline hydrochloride, the market is slightly calm, the average market transaction price of oxytetracycline is 86, and the price in the past three years has remained in the range of 75-87; the market for oxytetracycline hydrochloride was stable in the first half of the year, and the average market transaction price 104. The peak period appeared in 2019, the price has a record of breaking through 200, it will remain around 140 in 2020, and around 114 in 2021
Chlortetracycline hydrochloride, smooth operation
Flumethiamycin, market price 390
Florfenicol, the price fluctuated and stopped falling, rebounded slightly, the market price was 449-468, and the price in the same period last year was 590, down 18.1% year-on-year. The average prices in the past five weeks were: 479, 472, 460, 456, 460, nearly four The monthly price is maintained within 500, and the Asia-Pacific Easy and Data Analysis Center focuses on products
Aminoglycosides
Neomycin sulfate, the transaction price was stable in July, the quotation range was 145-156, the transaction price in the first half of the year was stable at around 150, and the price in the same period last year was 146
Spectinomycin hydrochloride (sulfuric acid), the transaction price is stable, the market price is around 540, down 1.1% month-on-month, down 2.8% year-on-year, the price in 2021 is 556, and the price in the same period in 2020 is 562
Gentamicin sulfate, the market is stable
Streptomycin sulfate, rose slightly, market price 265-289
The price of apramycin sulfate has been stable and decreased in the past two months. The market price is around 194, which is a historical low.
Monosulfate kanamycin, slightly lower than last week, the average market transaction price is 305, and the transaction price is stable in the first half of this year
Macrolides, peptides and others
In the second half of the year, the price of tilmicosin and tilmicosin phosphate has successfully exceeded 10 yuan/catties, and the price has risen nationwide. The good news affects the changes in macrolide products. The average transaction price of tilmicosin is 345, the price in the same period in 2021 is 423, and the price in the same period in 2020 is 345; the market price of tilmicosin phosphate is 320-332, which is flat month-on-month and down 16.6% year-on-year.
The price of tylosin tartrate fell slightly, the supply of the trading market was sufficient, and the market price was 240-256. The overall market in the first half of this year showed a downward trend, from 310 in January to below 240 in March, the price began to rebound at the end of April, and in May It rebounded to above 265, and fell below 260 in June.
Tyvalosin tartrate is running smoothly, the market price is around 540, and the price in the same period last year is 800. The price has dropped significantly, down 29.1% year-on-year. In the first half of 2022, there is a downward trend, from 600 in January, to about 540 in June
Guitaromycin tartrate, market price 288
Erythromycin thiocyanate, stable and strong, the market price is 370-380, a slight increase from the previous month, and a year-on-year increase of 1.2%
Colistin sulfate, the price is stable and down compared with last week, the market price is around 110
Tiamulin fumarate, low price
Lincomycin hydrochloride, the price is down, the transaction price range is 290-310, the price has been showing a downward trend in the first half of the year, and the price in the same period last year was 332. The average prices in the first half of the year are: 320, 318, 313, 305, 305, and 303 from January to June. The first half of 2021 is an upward trend, and the highest price appears in April at 355
Looking for chemical products? Let suppliers reach out to you!
2026-07-11
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Market Analysis of Domestic Veterinary Drug Raw Materials in the 34th Week of 2022
-
Analysis of China's Veterinary Drug Raw Material Market in the 32nd Week of 2022(1)
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
Recommend Reading
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
March adipic acid prices see a significant increase in China
-
Firm Costs and Weak Demand Lead to High-Level Fluctuations in the Chinese PTA Market
-
How Geopolitical Conflicts in the Middle East Ignite the Melamine Market with a Monthly Price Increase of Nearly 27% in China!
-
Cost-Driven Dichloromethane Prices Rise Over 35% in March
-
Domestic SBR Market Shows Strong Unilateral Increase